96 related articles for article (PubMed ID: 18496770)
1. The three nucleotide deletion within the 3'untranslated region of MLH1 resulting in gene expression reduction is not a causal alteration in Lynch syndrome.
Tinat J; Baert-Desurmont S; Latouche JB; Vasseur S; Martin C; Bouvignies E; Frébourg T
Fam Cancer; 2008; 7(4):339-40. PubMed ID: 18496770
[No Abstract] [Full Text] [Related]
2. Two new MLH1 germline mutations in Brazilian Lynch syndrome families.
Dominguez MV; Bastos EP; Santos EM; Oliveira LP; Ferreira FO; Carraro DM; Rossi BM
Int J Colorectal Dis; 2008 Dec; 23(12):1263-4. PubMed ID: 18594839
[No Abstract] [Full Text] [Related]
3. Lynch syndrome associated with two MLH1 promoter variants and allelic imbalance of MLH1 expression.
Hesson LB; Packham D; Kwok CT; Nunez AC; Ng B; Schmidt C; Fields M; Wong JW; Sloane MA; Ward RL
Hum Mutat; 2015 Jun; 36(6):622-30. PubMed ID: 25762362
[TBL] [Abstract][Full Text] [Related]
4. Identifying Lynch syndrome.
de la Chapelle A; Palomaki G; Hampel H
Int J Cancer; 2009 Sep; 125(6):1492-3. PubMed ID: 19536819
[No Abstract] [Full Text] [Related]
5. Gene symbol: MLH1.
Kadiyska TK; Bogdanova N
Hum Genet; 2007 Feb; 120(6):907. PubMed ID: 17235623
[No Abstract] [Full Text] [Related]
6. Segregation of a novel MLH1 mutation in an Iranian Lynch syndrome family.
Ghafouri-Fard S; Fardaei M; Lankarani KB; Miryounesi M
Gene; 2015 Oct; 570(2):304-5. PubMed ID: 26149658
[TBL] [Abstract][Full Text] [Related]
7. Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome.
Morak M; Koehler U; Schackert HK; Steinke V; Royer-Pokora B; Schulmann K; Kloor M; Höchter W; Weingart J; Keiling C; Massdorf T; Holinski-Feder E;
J Med Genet; 2011 Aug; 48(8):513-9. PubMed ID: 21712435
[TBL] [Abstract][Full Text] [Related]
8. Concomitant mutation and epimutation of the MLH1 gene in a Lynch syndrome family.
Cini G; Carnevali I; Quaia M; Chiaravalli AM; Sala P; Giacomini E; Maestro R; Tibiletti MG; Viel A
Carcinogenesis; 2015 Apr; 36(4):452-8. PubMed ID: 25742745
[TBL] [Abstract][Full Text] [Related]
9. Gene symbol: MLH1. Disease: Hereditary nonpolyposis colorectal cancer.
Otway R; Tetlow N; Hornby J; Doe WF; Kohonen-Corish MR
Hum Genet; 2005 May; 116(6):535. PubMed ID: 15991306
[No Abstract] [Full Text] [Related]
10. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients.
Alemayehu A; Sebova K; Fridrichova I
Genes Chromosomes Cancer; 2008 Oct; 47(10):906-14. PubMed ID: 18618713
[TBL] [Abstract][Full Text] [Related]
11. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome.
Niessen RC; Hofstra RM; Westers H; Ligtenberg MJ; Kooi K; Jager PO; de Groote ML; Dijkhuizen T; Olderode-Berends MJ; Hollema H; Kleibeuker JH; Sijmons RH
Genes Chromosomes Cancer; 2009 Aug; 48(8):737-44. PubMed ID: 19455606
[TBL] [Abstract][Full Text] [Related]
12. Gene symbol: MLH1. Disease: colorectal cancer, non-polyposis.
Kadiyska TK; Bogdanova N
Hum Genet; 2006 Apr; 119(3):360. PubMed ID: 17230646
[No Abstract] [Full Text] [Related]
13. Evaluation of MLH1 I219V polymorphism in unrelated South American individuals suspected of having Lynch syndrome.
Valentin MD; Da Silva FC; Santos EM; Da Silva SD; De Oliveira Ferreira F; Aguiar Junior S; Gomy I; Vaccaro C; Redal MA; Della Valle A; Sarroca C; Rasmussen LJ; Carraro DM; Rossi BM
Anticancer Res; 2012 Oct; 32(10):4347-51. PubMed ID: 23060557
[TBL] [Abstract][Full Text] [Related]
14. Cancer risk assessment in Lynch syndrome: does the gene matter?
Xicola RM; Llor X
JAMA; 2011 Jun; 305(22):2351-2. PubMed ID: 21642691
[No Abstract] [Full Text] [Related]
15. MLH1 constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria.
Crucianelli F; Tricarico R; Turchetti D; Gorelli G; Gensini F; Sestini R; Giunti L; Pedroni M; Ponz de Leon M; Civitelli S; Genuardi M
Epigenetics; 2014 Oct; 9(10):1431-8. PubMed ID: 25437057
[TBL] [Abstract][Full Text] [Related]
16. Letter in response to "Identifying Lynch syndrome" by de la Chapelle et al.
Jenkins MA; Dowty JG; Hopper JL; Tucker K; Southey MC
Int J Cancer; 2010 Jun; 126(11):2757-8. PubMed ID: 19847809
[No Abstract] [Full Text] [Related]
17. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.
Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N
Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639
[TBL] [Abstract][Full Text] [Related]
18. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
19. Germ line MLH1 and MSH2 mutations in Taiwanese Lynch syndrome families: characterization of a founder genomic mutation in the MLH1 gene.
Tang R; Hsiung C; Wang JY; Lai CH; Chien HT; Chiu LL; Liu CT; Chen HH; Wang HM; Chen SX; Hsieh LL;
Clin Genet; 2009 Apr; 75(4):334-45. PubMed ID: 19419416
[TBL] [Abstract][Full Text] [Related]
20. Molecular screening for Lynch syndrome: from bench to bedside.
Jensen LH; Lindebjerg J; Kølvraa S; Crüger DG
J Clin Oncol; 2009 Dec; 27(34):e224; author reply e225. PubMed ID: 19858372
[No Abstract] [Full Text] [Related]
[Next] [New Search]
